Literature DB >> 20080964

Agonist-regulated cleavage of the extracellular domain of parathyroid hormone receptor type 1.

Christoph Klenk1, Stefan Schulz, Davide Calebiro, Martin J Lohse.   

Abstract

The receptor for parathyroid hormone (PTHR) is a main regulator of calcium homeostasis and bone maintenance. As a member of class B of G protein-coupled receptors, it harbors a large extracellular domain, which is required for ligand binding. Here, we demonstrate that the PTHR extracellular domain is cleaved by a protease belonging to the family of extracellular metalloproteinases. We show that the cleavage takes place in a region of the extracellular domain that belongs to an unstructured loop connecting the ligand-binding parts and that the N-terminal 10-kDa fragment is connected to the receptor core by a disulfide bond. Cleaved receptor revealed reduced protein stability compared with noncleaved receptor, suggesting degradation of the whole receptor. In the presence of the agonistic peptides PTH(1-34), PTH(1-14), or PTH(1-31), the processing of the PTHR extracellular domain was inhibited, and receptor protein levels were stabilized. A processed form of the PTHR was also detected in human kidney. These findings suggest a new model of PTHR processing and regulation of its stability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080964      PMCID: PMC2838289          DOI: 10.1074/jbc.M109.058685

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

Review 2.  Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.

Authors:  Jean-Marie Delaissé; Thomas L Andersen; Michael T Engsig; Kim Henriksen; Tine Troen; Laurence Blavier
Journal:  Microsc Res Tech       Date:  2003-08-15       Impact factor: 2.769

3.  The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern.

Authors:  U Grauschopf; H Lilie; K Honold; M Wozny; D Reusch; A Esswein; W Schäfer; K P Rücknagel; R Rudolph
Journal:  Biochemistry       Date:  2000-08-01       Impact factor: 3.162

4.  Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues.

Authors:  Amelie Lupp; Christoph Klenk; Christoph Röcken; Matthias Evert; Christian Mawrin; Stefan Schulz
Journal:  Eur J Endocrinol       Date:  2010-02-15       Impact factor: 6.664

5.  Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation.

Authors:  Alexandre Trifilieff; Christoph Walker; Thomas Keller; Georg Kottirsch; Ulf Neumann
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  Dual regulation of the parathyroid hormone (PTH)/PTH-related peptide receptor signaling by protein kinase C and beta-arrestins.

Authors:  Marián Castro; Frank Dicker; Jean-Pierre Vilardaga; Cornelius Krasel; Manfred Bernhardt; Martin J Lohse
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

7.  Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor.

Authors:  N Shimizu; J Guo; T J Gardella
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

8.  In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass.

Authors:  Valérie Geoffroy; Caroline Marty-Morieux; Nathalie Le Goupil; Phillippe Clement-Lacroix; Catherine Terraz; Monique Frain; Sophie Roux; Jérome Rossert; Marie Christine de Vernejoul
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

9.  Parathyroid hormone inhibits the expression of membrane-type matrix metalloproteinase-1 (MT1-MMP) in osteoblast-like MG-63 cells.

Authors:  Xiang-hang Luo; Er-yuan Liao; Xin Su; Xian-ping Wu
Journal:  J Bone Miner Metab       Date:  2004       Impact factor: 2.626

10.  Measurement of the millisecond activation switch of G protein-coupled receptors in living cells.

Authors:  Jean-Pierre Vilardaga; Moritz Bünemann; Cornelius Krasel; Mariàn Castro; Martin J Lohse
Journal:  Nat Biotechnol       Date:  2003-06-15       Impact factor: 54.908

View more
  5 in total

1.  Site-specific O-Glycosylation by Polypeptide N-Acetylgalactosaminyltransferase 2 (GalNAc-transferase T2) Co-regulates β1-Adrenergic Receptor N-terminal Cleavage.

Authors:  Christoffer K Goth; Hanna E Tuhkanen; Hamayun Khan; Jarkko J Lackman; Shengjun Wang; Yoshiki Narimatsu; Lasse H Hansen; Christopher M Overall; Henrik Clausen; Katrine T Schjoldager; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2017-02-06       Impact factor: 5.157

2.  Ubiquitination-deubiquitination balance dictates ligand-stimulated PTHR sorting.

Authors:  Verónica Alonso; Clara E Magyar; Bin Wang; Alessandro Bisello; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

Review 3.  SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.

Authors:  Wei-Sheng Tien; Jun-Hong Chen; Kun-Pin Wu
Journal:  BMC Bioinformatics       Date:  2017-03-14       Impact factor: 3.169

4.  High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist.

Authors:  Janosch Ehrenmann; Jendrik Schöppe; Christoph Klenk; Mathieu Rappas; Lutz Kummer; Andrew S Doré; Andreas Plückthun
Journal:  Nat Struct Mol Biol       Date:  2018-11-19       Impact factor: 15.369

5.  Proteolytic Cleavage of the Extracellular Domain Affects Signaling of Parathyroid Hormone 1 Receptor.

Authors:  Christoph Klenk; Leif Hommers; Martin J Lohse
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.